PAVmed Inc. (NASDAQ:PAVM) is reporting second quarter earnings results on Tuesday 18th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.1 per share from $ 0.25 million in revenue.
For the full year, analysts predict revenues of $ 1.00 million, while looking forward to loss of $ 0.4 per share.
Previous Quarter Performance
PAVmed Inc. revealed loss for the first quarter of $ 0.10 per share, from the revenue of . The quarterly revenues compared with the same quarter last year. The consensus estimates are loss of $ 0.11 per share The bottom line results beat street analysts by $ 0.01 or 9.09 percent, at the same time, top line results analysts by $ 0.64 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
The company has a market capital of $ 102.13 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”PAVM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
PAVmed Inc. will be hosting a conference call at 4:30 PM eastern time on 18th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.pavmed.com
PAVmed Inc. operates as a medical device company in the United States. The companys lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
